Explore

Trendline Trendline
Amazon Expands Healthcare Offerings with Medicare Weight-Loss Drug Program

Amazon Expands Healthcare Offerings with Medicare Weight-Loss Drug Program

Amazon Expands Healthcare Offerings with Medicare Weight-Loss Drug Program
Trendline Trendline
Eli Lilly and Novo Nordisk Show Diverging Paths in Obesity Drug Market

Eli Lilly and Novo Nordisk Show Diverging Paths in Obesity Drug Market

Eli Lilly and Novo Nordisk Show Diverging Paths in Obesity Drug Market
USA Today USA Today
Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America's CEO said the company spends more than $250 million a year on GLP-1 drugs for employees, calling the growing cost a worthwhile investment.
Trendline Trendline
Novo Nordisk CEO Resets Expectations for Wegovy's Growth Amid Market Competition

Novo Nordisk CEO Resets Expectations for Wegovy's Growth Amid Market Competition

Novo Nordisk CEO Resets Expectations for Wegovy's Growth Amid Market Competition
Trendline Trendline
Eli Lilly Outpaces Novo Nordisk in Obesity Drug Market Amid Earnings Reports

Eli Lilly Outpaces Novo Nordisk in Obesity Drug Market Amid Earnings Reports

Eli Lilly Outpaces Novo Nordisk in Obesity Drug Market Amid Earnings Reports
Trendline Trendline
Eli Lilly's Mounjaro and Zepbound Sales Surge, Outpacing Novo Nordisk

Eli Lilly's Mounjaro and Zepbound Sales Surge, Outpacing Novo Nordisk

Eli Lilly's Mounjaro and Zepbound Sales Surge, Outpacing Novo Nordisk
Trendline Trendline
Eli Lilly Increases 2026 Revenue Forecast Following Strong Q2 Performance

Eli Lilly Increases 2026 Revenue Forecast Following Strong Q2 Performance

Eli Lilly Increases 2026 Revenue Forecast Following Strong Q2 Performance
Trendline Trendline
Novo Nordisk Faces Stock Decline Due to Pipeline Challenges

Novo Nordisk Faces Stock Decline Due to Pipeline Challenges

Novo Nordisk Faces Stock Decline Due to Pipeline Challenges
TheStreet TheStreet
Novo Nordisk CEO resets expectations for Wegovy's explosive growth

Novo Nordisk CEO resets expectations for Wegovy's explosive growth

I believe that when a stock is down nearly 10% year to date and down 38% over three years, the CEO's job on a quarterly earnings call is not just to report results. It is to rebuild a narrative that investors have lost confidence in. And Novo Nordisk CEO Mike Doustdar is honestly trying that with ...
Trendline Trendline
Novo Nordisk CEO Rules Out Large-Scale M Amid Competitive Pressures

Novo Nordisk CEO Rules Out Large-Scale M Amid Competitive Pressures

Novo Nordisk CEO Rules Out Large-Scale M Amid Competitive Pressures
Trendline Trendline
Eli Lilly Reports 48% Revenue Surge in Q2 2026 Driven by Incretin Portfolio

Eli Lilly Reports 48% Revenue Surge in Q2 2026 Driven by Incretin Portfolio

Eli Lilly Reports 48% Revenue Surge in Q2 2026 Driven by Incretin Portfolio
Trendline Trendline
Eli Lilly's Q2 Earnings Surpass Expectations, Driven by GLP-1 Drugs

Eli Lilly's Q2 Earnings Surpass Expectations, Driven by GLP-1 Drugs

Eli Lilly's Q2 Earnings Surpass Expectations, Driven by GLP-1 Drugs